What is the 13F Pro Quality Score for FTRE?

13F Pro ranks Fortrea Holdings Inc. (FTRE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FTRE's current score at https://13fpro.ai/research/FTRE (free sign-up required for the full ranking).

Which hedge funds own the most FTRE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of FTRE include BlackRock,, GOLDMAN SACHS GROUP, Corvex Management. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/FTRE as soon as new 13F filings post.

Where does 13F Pro source FTRE data?

All Fortrea Holdings Inc. fundamentals and ownership data come directly from SEC EDGAR. Fortrea Holdings Inc. files with the SEC under CIK 1965040. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FTRE in?

Fortrea Holdings Inc. (FTRE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FTRE research updated on 13F Pro?

FTRE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Fortrea Holdings Inc.(FTRE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1965040 FTRE stock profile & AI dashboard →

13F Pro Quality Score

31.4/100

Rank #2,317 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

31.3/100

Profitability

11.7/100

Balance Sheet

5.9/100

Earnings Quality

30.0/100

Free Cash Flow

28.7/100

Institutional Flow

84.0/100

Revenue Scale

67.6/100

Dilution Risk

35.6/100

FTRE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Fortrea Holdings Inc. (FTRE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FTRE at 31.4/100 on a 32-signal composite quality model, placing it at rank #2,317 of 2,879 stocks — the bottom half of the AI-ranked universe. FTRE scores in the top quartile across institutional flow (84.0). Areas of concern include balance sheet strength (5.9) and profitability (11.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 35.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Fortrea Holdings Inc. reports quarterly revenue of $636.5M, net income of $-23.6M, free cash flow of $-25.0M. Top institutional holders of FTRE by reported 13-F value include BlackRock,, GOLDMAN SACHS GROUP, Corvex Management, based on the most recent SEC filings. FTRE trades on the Nasdaq exchange and files with the SEC under CIK 1965040. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FTRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fortrea Holdings Inc. directly from SEC EDGAR. Fortrea Holdings Inc.'s 13F Pro composite quality score has ranged between 22 and 42 since 2024, currently 31.4 — a declining long-term trajectory across 18 quarterly and live scoring snapshots.

✦

Fun facts about Fortrea Holdings Inc.

Quirks, history, and lore behind FTRE — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mid-cap · listed on Nasdaq · headquartered in North Carolina.
2
The Numbers
Generates roughly $3 billion in annual revenue and operates across more than 90 countries — because drug pipelines don't respect borders.
3
The History
Spun off from Labcorp in 2023, it became an independent publicly traded company carrying decades of clinical research heritage into a new chapter.
4
The Secret
It doesn't make drugs — it tests them for everyone else, running clinical trials and laboratory services that help pharma and biotech companies get their products approved.
5
The Lore
With roughly 19,000 employees worldwide, it is one of the largest contract research organizations (CROs) on the planet — the unsung backbone of modern medicine.
6
The Giveaway
A Labcorp spinoff that kept the clinical trials business, traded under the ticker FTRE, and named itself something that sounds like a Latin word for strength.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$636.5M

Net Income

Q1 2026

$-23.6M

Free Cash Flow

Q1 2026

$-25.0M

D/E Ratio

Q1 2026

2.00

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.0% YoY

$2.72BFY 2025

FY21 $3.06BFY22 $2.84BFY24 $2.70BFY25 $2.72B

Net Income

-199.8% YoY

$-986.2MFY 2025

FY21 $98.0MFY22 $186.2MFY24 $-329.0MFY25 $-986.2M

Operating Income

-439.0% YoY

$-872.6MFY 2025

FY21 $114.3MFY22 $187.1MFY24 $-161.9MFY25 $-872.6M

EPS (Diluted)

-194.6% YoY

$-10.81FY 2025

FY21 $1.10FY22 $2.09FY24 $-3.67FY25 $-10.81

Total Assets

-24.1% YoY

$2.72BFY 2025

FY21 —FY22 $4.29BFY24 $3.58BFY25 $2.72B

Total Debt

-6.4% YoY

$1.05BFY 2025

FY21 —FY22 $0.00FY24 $1.12BFY25 $1.05B

Op. Cash Flow

-56.8% YoY

$113.5MFY 2025

FY21 $169.8MFY22 $82.7MFY24 $262.8MFY25 $113.5M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Revenue	$2.72B +1.0%	$2.70B -5.0%	$2.84B -7.2%	$3.06B	—
Net Income	$-986.2M -199.8%	$-329.0M -276.7%	$186.2M +90.0%	$98.0M	—
Operating Income	$-872.6M -439.0%	$-161.9M -186.5%	$187.1M +63.7%	$114.3M	—
EPS (Diluted)	$-10.81 -194.6%	$-3.67 -275.6%	$2.09 +90.0%	$1.10	—
Total Assets	$2.72B -24.1%	$3.58B -16.5%	$4.29B	—	—
Total Debt	$1.05B -6.4%	$1.12B	$0.00	—	—
Operating Cash Flow	$113.5M -56.8%	$262.8M +217.8%	$82.7M -51.3%	$169.8M	—

Get alerted when FTRE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Fortrea Holdings Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FTRE

BlackRock, Inc.
$142.7M15,152,395 sh
GOLDMAN SACHS GROUP INC
$76.3M8,098,517 sh
Corvex Management LP
$43.7M4,644,193 sh
Sessa Capital IM, L.P.
$43.3M4,593,550 sh
STATE STREET CORP
$38.7M4,109,400 sh
VANGUARD CAPITAL MANAGEMENT LLC
$38.0M4,038,562 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$34.8M3,696,749 sh
AQR CAPITAL MANAGEMENT LLC
$30.5M3,298,421 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$30.2M3,207,673 sh
DEUTSCHE BANK AG\
$24.2M2,569,274 sh

Fund	Value	Shares
BlackRock, Inc.	$142.7M	15,152,395
GOLDMAN SACHS GROUP INC	$76.3M	8,098,517
Corvex Management LP	$43.7M	4,644,193
Sessa Capital IM, L.P.	$43.3M	4,593,550
STATE STREET CORP	$38.7M	4,109,400
VANGUARD CAPITAL MANAGEMENT LLC	$38.0M	4,038,562
VANGUARD PORTFOLIO MANAGEMENT LLC	$34.8M	3,696,749
AQR CAPITAL MANAGEMENT LLC	$30.5M	3,298,421
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$30.2M	3,207,673
DEUTSCHE BANK AG\	$24.2M	2,569,274

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FTRE on your watchlist

Track score changes the day Fortrea Holdings Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FTRE a good stock to buy?

13F Pro's AI-powered analysis of Fortrea Holdings Inc. (FTRE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FTRE are available on the FTRE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own FTRE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FTRE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Fortrea Holdings Inc.'s investment landscape.